Overview

Study to Determine the Tolerability, Safety and Pharmacokinetics of Ketorolac Tromethamine by Intranasal Administration in Healthy Volunteers

Status:
Completed

Trial end date:
2006-09-01

Target enrollment:

Participant gender:

Summary

This was a phase 1, open label, multiple dose study in healthy male and female volunteers. Subjects received intranasal ketorolac tromethamine (30 mg) three times daily (t.i.d.) for three days (seven doses in total). Doses were administered every eight hours. The objective of this study in healthy volunteers was to determine the safety, tolerability, and pharmacokinetics of multiple doses of intranasal ketorolac tromethamine.

Phase:

Phase 1

Details

Lead Sponsor:

Egalet Ltd

Treatments:

Ketorolac
Ketorolac Tromethamine